NCT05875025View on ClinicalTrials.gov

Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 26, 2023

Primary Completion Date

September 8, 2023

Study Completion Date

September 8, 2023

Conditions
Mucociliary Clearance
Interventions
OTHER

Placebo formulated with HFA-152a propellant via pMDI

5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8

OTHER

Placebo formulated with HFA-134a propellant via pMDI

5 inhalations BID (morning and evening) for 8 consecutive days, starting from the morning of Day 1 until the morning of Day 8

Trial Locations (1)

G4 0SF

BDD Pharma - Bio-Imaging Centre, Glasgow

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT05875025 - Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance | Biotech Hunter | Biotech Hunter